PL427370A1 - Method of determining the risk of death in a patient diagnosed with laryngeal cancer - Google Patents
Method of determining the risk of death in a patient diagnosed with laryngeal cancerInfo
- Publication number
- PL427370A1 PL427370A1 PL427370A PL42737018A PL427370A1 PL 427370 A1 PL427370 A1 PL 427370A1 PL 427370 A PL427370 A PL 427370A PL 42737018 A PL42737018 A PL 42737018A PL 427370 A1 PL427370 A1 PL 427370A1
- Authority
- PL
- Poland
- Prior art keywords
- concentration
- death
- risk
- determining
- laryngeal cancer
- Prior art date
Links
- 206010023825 Laryngeal cancer Diseases 0.000 title abstract 2
- 206010023841 laryngeal neoplasm Diseases 0.000 title abstract 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 abstract 3
- 229910052725 zinc Inorganic materials 0.000 abstract 3
- 239000011701 zinc Substances 0.000 abstract 3
- 239000008280 blood Substances 0.000 abstract 2
- 210000004369 blood Anatomy 0.000 abstract 2
- 229910052793 cadmium Inorganic materials 0.000 abstract 2
- BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 abstract 2
- 239000012620 biological material Substances 0.000 abstract 1
- 210000002966 serum Anatomy 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/84—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving inorganic compounds or pH
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/70—Mechanisms involved in disease identification
- G01N2800/7023—(Hyper)proliferation
- G01N2800/7028—Cancer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Inorganic Chemistry (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Przedmiotem zgłoszenia jest sposób określania ryzyka zgonu chorego ze zdiagnozowanym rakiem krtani. Sposób ten charakteryzuje się tym, że w pobranym od pacjenta materiale biologicznym bada się stężenie cynku i/lub kadmu i porównuje ich poziom z wzorcem, przy czym obniżone ryzyko zgonu stwierdza się w przypadku stężenia cynku odpowiadającego stężeniu w surowicy wyższemu niż 580 µg/l, stężenia cynku odpowiadającego stężeniu we krwi wyższemu niż 5700 µg/l lub stężenia kadmu odpowiadającego stężeniu we krwi niższego od 0,80 µg/l.The subject of the application is the method of determining the risk of death in a patient diagnosed with laryngeal cancer. This method is characterized by the fact that the concentration of zinc and / or cadmium in the biological material collected from the patient is tested and their level compared with a standard, with a reduced risk of death being found at a concentration of zinc corresponding to a serum concentration higher than 580 µg / l, a zinc concentration corresponding to a blood concentration of more than 5700 µg / l or a cadmium concentration corresponding to a blood concentration of less than 0.80 µg / l.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PL427370A PL244460B1 (en) | 2018-10-10 | 2018-10-10 | Method of determining the risk of death in a patient diagnosed with laryngeal cancer |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PL427370A PL244460B1 (en) | 2018-10-10 | 2018-10-10 | Method of determining the risk of death in a patient diagnosed with laryngeal cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| PL427370A1 true PL427370A1 (en) | 2020-04-20 |
| PL244460B1 PL244460B1 (en) | 2024-01-29 |
Family
ID=70281516
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL427370A PL244460B1 (en) | 2018-10-10 | 2018-10-10 | Method of determining the risk of death in a patient diagnosed with laryngeal cancer |
Country Status (1)
| Country | Link |
|---|---|
| PL (1) | PL244460B1 (en) |
-
2018
- 2018-10-10 PL PL427370A patent/PL244460B1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PL244460B1 (en) | 2024-01-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY200034A (en) | Radiolabeled anti-lag3 antibodies for immuno-pet imaging | |
| EA201492105A1 (en) | IMMUNOTHERAPY OF MALIGNANT TUMORS BY DISTURBING TRANSMISSION OF SIGNALS PD-1 / PD-L1 | |
| BR112015022934A2 (en) | neuroactive steroids, compositions, and use thereof | |
| MX2009011228A (en) | Detection her-2/neu protein from non-isolated circulating cancer cells and treatment. | |
| WO2017062496A3 (en) | Anti-sas1b antibodies, associated methods of use, and compositions and methods for detecting and treating cancer | |
| ZA202102071B (en) | Use of soluble trem-1 levels for identifying subjects susceptible to respond to an anti-inflammatory therapy | |
| SG10201806729VA (en) | Novel assay to detect human periostin | |
| PL437046A1 (en) | Serum arsenic, zinc and selenium concentration as a marker of survival in patients with prostate cancer in Poland | |
| PL427370A1 (en) | Method of determining the risk of death in a patient diagnosed with laryngeal cancer | |
| MX2022002886A (en) | RADIOLABELED MET UNION PROTEINS FOR IMAGING BY IMMUNO-PET. | |
| CY1125204T1 (en) | METHOD FOR DETERMINING GROWTH HORMONE DEFICIENCY IN HUMANS WITH A COMPOSITION CONTAINING MACIMORELIN | |
| EA202190671A1 (en) | IMMUNOGENETIC SCREENING TEST FOR CANCER | |
| PL439314A1 (en) | Method for determining the risk of cancers in women, depending on concentration of cadmium in the blood | |
| PL439316A1 (en) | How to determine the risk of cancer in women according to the concentration of zinc in the blood | |
| EA202091415A1 (en) | METHOD FOR ASSESSING GROWTH HORMONE DEFICIENCY IN HUMANS USING A COMPOSITION CONTAINING MATSIMORELIN | |
| PL439315A1 (en) | The method of determining the risk of cancer in women depending on the concentration of selenium in the blood | |
| PL421781A1 (en) | Method for detecting significantly decreased risk of cancers in men in Poland, through assessment of arsenic concentration in blood | |
| PL433150A1 (en) | Method for determining the risk of cancers in women with BRCA1 mutations, depending on blood lead level | |
| PL417616A1 (en) | Concentration of selenium as a prognostic marker in persons with larynx cancer in Poland | |
| PL415644A1 (en) | Concentration of iron in blood as a risk factor for cancers in women after the age of 50 | |
| PL439313A1 (en) | Method for determining the risk of cancers in women, depending on concentration of arsenic in the blood | |
| PL439319A1 (en) | The method of determining the risk of cancer in women depending on the zinc in the blood of women who are carriers of the most common mutations in the BRCA1 and BRCA2 genes | |
| PL414268A1 (en) | Concentration of zinc in blood within IL6 gene as risk factors for cancers in women | |
| PL437608A1 (en) | Method of determining the risk of cancer in women according to the concentration of cadmium in the blood | |
| PL415640A1 (en) | Concentration of iron in blood and changes within HFE gene as risk factors for cancers in women |